Titre : Protéines à répétitions de séquences bêta-transducine

Protéines à répétitions de séquences bêta-transducine : Questions médicales fréquentes

Termes MeSH sélectionnés :

Data Accuracy
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Protéines à répétitions de séquences bêta-transducine : Questions médicales les plus fréquentes", "headline": "Protéines à répétitions de séquences bêta-transducine : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Protéines à répétitions de séquences bêta-transducine : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-05-05", "dateModified": "2025-04-30", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Protéines à répétitions de séquences bêta-transducine" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines F-box", "url": "https://questionsmedicales.fr/mesh/D044783", "about": { "@type": "MedicalCondition", "name": "Protéines F-box", "code": { "@type": "MedicalCode", "code": "D044783", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.157.169" } } }, "about": { "@type": "MedicalCondition", "name": "Protéines à répétitions de séquences bêta-transducine", "alternateName": "beta-Transducin Repeat-Containing Proteins", "code": { "@type": "MedicalCode", "code": "D044844", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Richard A Cerione", "url": "https://questionsmedicales.fr/author/Richard%20A%20Cerione", "affiliation": { "@type": "Organization", "name": "Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853, USA; Department of Molecular Medicine, Cornell University, Ithaca, NY 14853, USA. Electronic address: rac1@cornell.edu." } }, { "@type": "Person", "name": "Yang Gao", "url": "https://questionsmedicales.fr/author/Yang%20Gao", "affiliation": { "@type": "Organization", "name": "Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853, USA." } }, { "@type": "Person", "name": "Sekar Ramachandran", "url": "https://questionsmedicales.fr/author/Sekar%20Ramachandran", "affiliation": { "@type": "Organization", "name": "Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853, USA." } }, { "@type": "Person", "name": "Jon W Erickson", "url": "https://questionsmedicales.fr/author/Jon%20W%20Erickson", "affiliation": { "@type": "Organization", "name": "Department of Chemistry and Chemical Biology, Cornell University, Ithaca, NY 14853, USA." } }, { "@type": "Person", "name": "Yeonji Chang", "url": "https://questionsmedicales.fr/author/Yeonji%20Chang", "affiliation": { "@type": "Organization", "name": "Whitehead Institute for Biomedical Research, Cambridge, MA 02142." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Digital Health Data Quality Issues: Systematic Review.", "datePublished": "2023-03-31", "url": "https://questionsmedicales.fr/article/37000497", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2196/42615" } }, { "@type": "ScholarlyArticle", "name": "Perspective: A Comprehensive Evaluation of Data Quality in Nutrient Databases.", "datePublished": "2023-02-25", "url": "https://questionsmedicales.fr/article/36849083", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.advnut.2023.02.005" } }, { "@type": "ScholarlyArticle", "name": "Automating Electronic Health Record Data Quality Assessment.", "datePublished": "2023-02-13", "url": "https://questionsmedicales.fr/article/36781551", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s10916-022-01892-2" } }, { "@type": "ScholarlyArticle", "name": "Advances and innovations in methods for collecting egocentric network data.", "datePublished": "2022-11-07", "url": "https://questionsmedicales.fr/article/36470633", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.ssresearch.2022.102816" } }, { "@type": "ScholarlyArticle", "name": "Data Quality in Health Research: Integrative Literature Review.", "datePublished": "2023-10-31", "url": "https://questionsmedicales.fr/article/37906223", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.2196/41446" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines de transport", "item": "https://questionsmedicales.fr/mesh/D002352" }, { "@type": "ListItem", "position": 5, "name": "Protéines F-box", "item": "https://questionsmedicales.fr/mesh/D044783" }, { "@type": "ListItem", "position": 6, "name": "Protéines à répétitions de séquences bêta-transducine", "item": "https://questionsmedicales.fr/mesh/D044844" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Protéines à répétitions de séquences bêta-transducine - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Protéines à répétitions de séquences bêta-transducine", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-18", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Protéines à répétitions de séquences bêta-transducine", "description": "Comment diagnostiquer une anomalie des protéines bêta-transducine ?\nQuels tests sont utilisés pour évaluer les protéines bêta-transducine ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nY a-t-il des marqueurs spécifiques pour ces protéines ?\nPeut-on utiliser l'imagerie pour le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D044844?mesh_terms=Data+Accuracy&page=4#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Protéines à répétitions de séquences bêta-transducine", "description": "Quels symptômes sont associés aux dysfonctionnements des protéines ?\nLes symptômes sont-ils toujours présents ?\nY a-t-il des symptômes spécifiques à surveiller ?\nLes symptômes évoluent-ils avec le temps ?\nLes symptômes peuvent-ils être confondus avec d'autres maladies ?", "url": "https://questionsmedicales.fr/mesh/D044844?mesh_terms=Data+Accuracy&page=4#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Protéines à répétitions de séquences bêta-transducine", "description": "Peut-on prévenir les anomalies des protéines bêta-transducine ?\nY a-t-il des mesures préventives recommandées ?\nLes antécédents familiaux influencent-ils la prévention ?\nLe dépistage prénatal est-il possible ?\nLes vaccinations peuvent-elles aider ?", "url": "https://questionsmedicales.fr/mesh/D044844?mesh_terms=Data+Accuracy&page=4#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Protéines à répétitions de séquences bêta-transducine", "description": "Quels traitements sont disponibles pour les anomalies protéiques ?\nLa physiothérapie est-elle utile ?\nY a-t-il des traitements expérimentaux ?\nLes traitements sont-ils personnalisés ?\nLes traitements peuvent-ils guérir les anomalies ?", "url": "https://questionsmedicales.fr/mesh/D044844?mesh_terms=Data+Accuracy&page=4#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Protéines à répétitions de séquences bêta-transducine", "description": "Quelles complications peuvent survenir avec ces anomalies ?\nLes complications sont-elles réversibles ?\nY a-t-il des risques de maladies associées ?\nLes complications affectent-elles la qualité de vie ?\nComment gérer les complications ?", "url": "https://questionsmedicales.fr/mesh/D044844?mesh_terms=Data+Accuracy&page=4#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Protéines à répétitions de séquences bêta-transducine", "description": "Quels sont les principaux facteurs de risque ?\nL'âge joue-t-il un rôle dans le risque ?\nLes habitudes de vie influencent-elles le risque ?\nY a-t-il des facteurs environnementaux à considérer ?\nLes facteurs de risque sont-ils modifiables ?", "url": "https://questionsmedicales.fr/mesh/D044844?mesh_terms=Data+Accuracy&page=4#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une anomalie des protéines bêta-transducine ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur des tests génétiques et des analyses protéomiques." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer les protéines bêta-transducine ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests de Western blot et des techniques de spectrométrie de masse sont courants." } }, { "@type": "Question", "name": "Les biopsies sont-elles nécessaires pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Elles peuvent être nécessaires pour évaluer l'expression des protéines dans les tissus." } }, { "@type": "Question", "name": "Y a-t-il des marqueurs spécifiques pour ces protéines ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des marqueurs spécifiques peuvent être identifiés par des anticorps ciblés." } }, { "@type": "Question", "name": "Peut-on utiliser l'imagerie pour le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "L'imagerie peut aider à visualiser des anomalies associées, mais pas directement les protéines." } }, { "@type": "Question", "name": "Quels symptômes sont associés aux dysfonctionnements des protéines ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient, incluant des troubles neurologiques et des anomalies métaboliques." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours présents ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Non, certains individus peuvent être asymptomatiques malgré des anomalies protéiques." } }, { "@type": "Question", "name": "Y a-t-il des symptômes spécifiques à surveiller ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des troubles de la vision et des problèmes de coordination peuvent être observés." } }, { "@type": "Question", "name": "Les symptômes évoluent-ils avec le temps ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les symptômes peuvent s'aggraver ou évoluer selon la gravité de l'anomalie." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils être confondus avec d'autres maladies ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent ressembler à ceux d'autres troubles neurologiques ou métaboliques." } }, { "@type": "Question", "name": "Peut-on prévenir les anomalies des protéines bêta-transducine ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention est difficile, mais un dépistage génétique peut aider à identifier les risques." } }, { "@type": "Question", "name": "Y a-t-il des mesures préventives recommandées ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Des conseils sur le mode de vie sain et le suivi médical régulier sont recommandés." } }, { "@type": "Question", "name": "Les antécédents familiaux influencent-ils la prévention ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de maladies génétiques augmentent le risque." } }, { "@type": "Question", "name": "Le dépistage prénatal est-il possible ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le dépistage prénatal peut identifier certaines anomalies génétiques." } }, { "@type": "Question", "name": "Les vaccinations peuvent-elles aider ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Les vaccinations ne préviennent pas directement les anomalies protéiques, mais protègent la santé générale." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour les anomalies protéiques ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la thérapie génique et des médicaments ciblés." } }, { "@type": "Question", "name": "La physiothérapie est-elle utile ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la physiothérapie peut aider à améliorer la fonction motrice et la coordination." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Des essais cliniques évaluent de nouvelles approches thérapeutiques pour ces conditions." } }, { "@type": "Question", "name": "Les traitements sont-ils personnalisés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent être adaptés en fonction du profil génétique du patient." } }, { "@type": "Question", "name": "Les traitements peuvent-ils guérir les anomalies ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Certains traitements peuvent améliorer les symptômes, mais une guérison complète est rare." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec ces anomalies ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des troubles neurologiques graves et des déficits fonctionnels." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être gérées, mais beaucoup ne sont pas réversibles." } }, { "@type": "Question", "name": "Y a-t-il des risques de maladies associées ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les anomalies peuvent augmenter le risque de maladies métaboliques et cardiovasculaires." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent significativement réduire la qualité de vie des patients." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique un suivi médical régulier et des interventions thérapeutiques adaptées." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent des mutations génétiques, des antécédents familiaux et des expositions environnementales." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle dans le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, certains risques augmentent avec l'âge, notamment pour les maladies dégénératives." } }, { "@type": "Question", "name": "Les habitudes de vie influencent-elles le risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un mode de vie malsain peut exacerber les risques associés aux anomalies protéiques." } }, { "@type": "Question", "name": "Y a-t-il des facteurs environnementaux à considérer ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des toxines ou à des agents chimiques peut augmenter le risque." } }, { "@type": "Question", "name": "Les facteurs de risque sont-ils modifiables ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certains facteurs, comme le mode de vie, sont modifiables, d'autres non." } } ] } ] }

Sources (10000 au total)

Digital Health Data Quality Issues: Systematic Review.

The promise of digital health is principally dependent on the ability to electronically capture data that can be analyzed to improve decision-making. However, the ability to effectively harness data h... The aim of this study was to develop a consolidated digital health DQ dimension and outcome (DQ-DO) framework to provide insights into 3 research questions: What are the dimensions of digital health D... Following the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, a developmental systematic literature review was conducted of peer-reviewed literature focusing on... The digital health DQ-DO framework consists of 6 dimensions of DQ, namely accessibility, accuracy, completeness, consistency, contextual validity, and currency; interrelationships among the dimensions... The DQ-DO framework developed in this study demonstrates the complexity of digital health DQ and the necessity for reducing digital health DQ issues. The framework further provides health care executi...

Data Quality in Health Research: Integrative Literature Review.

Decision-making and strategies to improve service delivery must be supported by reliable health data to generate consistent evidence on health status. The data quality management process must ensure t... Through an integrative literature review, the aim of this work was to identify and evaluate digital health technology interventions designed to support the conducting of health research based on data ... A search was conducted in 6 electronic scientific databases in January 2022: PubMed, SCOPUS, Web of Science, Institute of Electrical and Electronics Engineers Digital Library, Cumulative Index of Nurs... After analyzing and extracting the outcomes of interest, 33 papers were included in the review. The studies covered the period of 2017-2021 and were conducted in 22 countries. Key findings revealed va... The main barriers to health data quality are technical, motivational, economical, political, legal, ethical, organizational, human resources, and methodological. The data quality process and technique... RR2-10.1101/2022.05.31.22275804....

Impact of monitoring approaches on data quality in clinical trials.

Source data verification (SDV) has been reported to account for up to 25% of the budget in clinical trials (CT) and cost-benefit of SDV has been questioned. Guidelines for risk-based monitoring (RBM) ... Data on residual errors from four, large comparable randomised CTs were examined by post-trial SDV. Observed discrepancies were analysed in the categories of "overall" data, "major efficacy" and "majo... A total of 1 716 087 data points were verified using CM and 323 174 using RBM. The overall error rate was 0.40% for RBM and 0.37% for CM (P < 0.01). For major efficacy, defined by risk assessment, the... These empirical data, directly comparing RBM with CM, suggest that RBM improves data quality regarding data-points of major importance to trial outcomes, efficacy and major safety. Overall, the RBM ap...

Data quality and timeliness analysis for post-vaccination adverse event cases reported through healthcare data exchange to FDA BEST pilot platform.

This study is part of the U.S. Food and Drug Administration (FDA)'s Biologics Effectiveness and Safety (BEST) initiative, which aims to improve the FDA's postmarket surveillance capabilities by using ... The study used RWD from 283 post-vaccination AE cases, which were received through the platform. We used descriptive statistics to report results and apply 322 data quality tests based on a data quali... The volume analysis indicated the average clinical resources for a post-vaccination AE case was 983.9 for the median partner. The query response time analysis indicated that cases could be received by... This study describes the platform's data volume, data query response time, and data quality results from the queried postvaccination adverse event cases and identified updates to current standards to ...

Data quality considerations for evaluating COVID-19 treatments using real world data: learnings from the National COVID Cohort Collaborative (N3C).

Multi-institution electronic health records (EHR) are a rich source of real world data (RWD) for generating real world evidence (RWE) regarding the utilization, benefits and harms of medical intervent... Using the National COVID Cohort Collaborative (N3C) enclave, we defined a patient population using criteria typical in non-interventional inpatient drug effectiveness studies. We present the challenge... We share our experiences and lessons learned when working with heterogeneous EHR data from over 65 healthcare institutions and 4 common data models. We discuss six key areas of data variability and qu... The creation of large scale centralized multi-site EHR databases such as N3C enables a wide range of research aimed at better understanding treatments and health impacts of many conditions including C...

Evaluating patient data quality in South Africa's National Health Laboratory Service Data Warehouse, 2017-2020: implications for monitoring child health programmes.

South Africa's National Health Laboratory Service (NHLS), the only clinical laboratory service in the country's public health sector, is an important resource for monitoring public health programmes.... We describe NHLS data quality, particularly patient demographics among infants, and the effect this has on linking multiple test results to a single patient.... Retrospective descriptive analysis of NHLS data from 1... During the period analysed, 485 300 007 tests, 98 217 642 encounters and 35 771 846 patients met criteria for analysis. Overall, 15.80% (n = 15 515 380) of all encounters had a registered national ide... Unavailability and poor capturing of patient demographics, especially among infants and children, affects the ability to accurately monitor routine health programmes. A unique national patient identif...